HIV-1 Drug Resistance in Mother–Infant Pairs in Southern Mozambique
Abstract
This prospective nested cohort (EARTH) study evaluated drug resistance mutations and outcomes among 79 (31 with genetic results) early-treated Mozambican children living with HIV, followed for 50 months. Mortality reached 20.3%. Drug resistance mutations were detected in 58.1% of children and 50.0% of mothers; 30% of pairs shared mutations. No integrase inhibitor resistance was detected, supporting Mozambique's transition to dolutegravir-based regimens.
// Source
Authors: David Torres-Fernández, Sheila Martínez Fernández, Sara Domínguez‐Rodríguez, Tacilta Nhampossa, Elisa López‐Varela, Maria Grazia Lain, Denise Naniche, Paula Vaz, Nália Ismael, Moira J. Spyer, Matthew Byott, Eleni Nastouli, Quique Bassat, Pablo Rojo, Paolo Rossi, Carlo Giaquinto, Alfredo Tagarro
Institutions: University of Padua, University College London, Universidad Complutense de Madrid, Instituto de Salud Carlos III, Barcelona Institute for Global Health, Institució Catalana de Recerca i Estudis Avançats, Research Institute Hospital 12 de Octubre, Centro de Investigación Biomédica en Red, Hospital Universitario 12 De Octubre, Universitat de Barcelona, University of Rome Tor Vergata, Universidad Europea de Madrid, Bambino Gesù Children's Hospital, Instituto Nacional de Saúde, Hospital Sant Joan de Déu Barcelona, University College London Hospitals NHS Foundation Trust, Manhiça Health Research Centre, Hospital Universitario Infanta Sofía, Centro de Investigación Biomédica en Red Enfermedades Infecciosas, Fundação Ariel Glaser Contra o SIDA Pediátrico, PENTA Foundation, Hospital Universitario del Henares